Steven Cohen’s Gyre Therapeutics GYRE Stock Holding History

Steven Cohen’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-80,047	Closed	-$7.01M	–	1078
2018 Q2	$7.01M	Buy	+80,047	New	+$14M	0.03%	529

Other funds holding GYRE

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Steven Cohen's GYRE Position: Q3 2018 in Review

Steven Cohen sold out of Gyre Therapeutics (GYRE) in Q3 2018, closing a stake of 80,047 shares — an estimated $7.01M sold.

Steven Cohen first reported a position in GYRE in Q2 2018 and held it in 1 quarter. The position peaked at $7.01M in Q2 2018. 70 funds tracked by Wall St. Rank hold GYRE as of Q3 2018.

Steven Cohen reported no remaining Gyre Therapeutics position as of Q3 2018 after selling out during the quarter.
Steven Cohen sold 80,047 Gyre Therapeutics shares in Q3 2018, an estimated $7.01M.
Steven Cohen first reported a position in Gyre Therapeutics in Q2 2018 and held it in 1 quarter.
Steven Cohen's Gyre Therapeutics position peaked at $7.01M in Q2 2018.
70 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2018.

Based on Point72 Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.